Praxis(US:PRAX) Newsfilter·2024-06-04 21:00Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance [1][4] - The company granted stock options and restricted stock units to a new non-executive employee as part of its 2024 Inducement Plan, which is designed to attract new talent [1][2] Stock Options and Awards - The Compensation Committee granted non-qualified stock options to purchase 300 shares and restricted stock units covering 225 shares to a new employee [1] - The options have an exercise price of $47.05 per share, equal to the closing price on the grant date, and will vest over four years [3] - The vesting schedule includes 25% vesting on the first anniversary and the remainder in equal monthly installments over the following three years, contingent on continued employment [3] Company Overview - Praxis utilizes genetic insights to develop therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [4] - The company has a diversified CNS portfolio with multiple programs across movement disorders and epilepsy, including four clinical-stage product candidates [4]